Breaking News, Financial News

Gilead Sciences

Antivirals lead the way, but EU challenges could hurt future revenues

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences 2Q10 2Q Revenues: $1.9 billion (+17%) 2Q Earnings: $712 million (+25%) YTD Revenues: $4.0 billion (+26%) YTD Earnings: $1.6 billion (+35%) Comments: Antiviral sales in 2Q10 rose 13% to $1.6 billion in 2Q10, led by Atripla (+26%, $716 million) and Truvada (+6%, $642 million). The company reduced its sales estimates for FY10 by $100 million, citing price challenges in the EU. Sales of pulmonary arterial hypertension treatment Letairis were up 37% to $60 million in 2Q...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters